Advanced searches left 3/3

Alk Gene - DOAJ

Summarized by Plex Scholar
Last Updated: 10 July 2022

* If you want to update the article please login/register

Identification of ALK gene alterations in urothelial carcinoma.

BACKGROUND: Anaplastic lymphoma kinase genomic alterations have emerged as a reliable predictor of cancer treatment with ALK inhibitors. There is currently no information regarding ALK gene mutations in urothelial carcinoma and its connection with clinical or pathologic features and outcome. In the FISH positive case, next generation sequencing was performed using Illumina Genome Analyzer IIx and Illumina HiSeq 2000. In 17 patients, chromosome 2 gain increases were discovered at arm level. aCGH discovered minor copy number variations in the vicinity of ALK locus in three patients. Sequence analysis at the coverage level used was inconclusive to reveal deletion at the level of the ALK gene at the level of the coverage level. The promise of evaluating ALK inhibitors in UC is worthy of further investigation, but it may be limited to the identification of an enriched population.

Source link: https://doi.org/10.1371/journal.pone.0103325


Real‐world data on EGFR/ALK gene status and first‐line targeted therapy rate in newly diagnosed advanced non‐small cell lung cancer patients in Northern China: A prospective observational study

Background Tyrosine kinase inhibitors may help patients with advanced non-u2010small cell lung cancer harboring epidermal growth factor receptor u2010 mutation or anaplastic lymphoma kinase kinase. Methods We conducted a prospective research involving 1134 patients with cytologically or histologically confirmed advanced NSCLC at 12 Chinese hospitals. The EGFR mutation prevalence in patients with squamous cell carcinoma was 8. 3% in patients with squamous cell carcinoma, and the ALK rearrangement rate was 37 percent. According to statistics, the median time from tumor diagnosis to EGFR or ALK status confirmation was 7 and 5 days. In EGFRu2010positive patients and 54% in ALKu2010positive patients, the targeted therapy rate was 78%, with 78% in EGFRu2010positive patients and 54% in ALKu2010positive patients. There was a negative correlation between the first and the EGFR mutation detection period of u2010line treatment, but there was no evidence between patients with ALK rearrangement. For Chinese patients with NSCLC, the first u2010line-targeted therapy success remains poor.

Source link: https://doi.org/10.1111/1759-7714.13090


Gain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type status.

According to ALK gene status, the results of 68 patients with advanced colorectal cancer and RAS-BRAF and PI3KCA wild-type metastatic colorectal cancer patients with KRAS-BRAF and PI3KCA wild-type metastatic colorectal cancer were determined in a broader group of molecularly enriched populations. Whether cetuximab and panitumumab show an elevated rate for patients with KRAS Patients with disomic ALK were significantly higher than those with a lack of gene copy number, according to those with an increase in gene copy number.

Source link: https://doi.org/10.1371/journal.pone.0092147


Clinical and computed tomography characteristics of non‐small cell lung cancer with ALK gene rearrangement: Comparison with EGFR mutation and ALK/EGFR‐negative lung cancer

Background The aim of this review was to analyze the clinical and computed tomography findings of non-u2010small cell lung cancer patients to determine between ALK gene rearrangement, EGFR mutation, and non-u2010ALK/EGFR. Methods We recruited 201 patients with primary NSCLC who had undergone molecular testing for both ALK gene rearrangement and EGFR mutations, which had undergone molecular testing. Patients with ALK gene rearrangement in NSCLC patients with ALK gene rearrangement were significantly less prevalent than nonu2010ALK/EGFR. Conclusions NSCLC with ALK gene rearrangement was more likely to occur in younger women with a light or no smoking history.

Source link: https://doi.org/10.1111/1759-7714.13017


Detection of ALK Gene Rearrangements in Non-Small Cell Lung Cancer by Immunocytochemistry and Fluorescence in Situ Hybridization on Cytologic Samples

The cases were classified as either ALK positive or negative on the basis of ALK protein expression on ICC. Using the Vysis ALK break apart FISH probe kit, 7 ALK ICC positive cases and 7 ALK ICC negative cases were conducted in 7 ALK ICC positive cases and 7 ALK ICC negative cases. Non-smokers were more likely to experience lung adenocarcinoma in non-smokers than in smokers. In five cases, FISH displayed break apart signal in five cases, but no break-apart signals were seen in two ALK-ICC positive and all the seven ALK-ICC negative cases. Conclusion: Immunocytochemistry on cell-blocks using DF53 clone is a highly sensitive and specific method for the detection of ALK gene rearrangements in lung adenocarcinoma, with a greater number of ALK positive cases on ICC compared to ALK-FISH.

Source link: https://doi.org/10.5146/tjpath.2021.01542


Unproductive Effects of ALK Gene Amplification and Copy Number Gain in Non-Small-Cell Lung Cancer. ALK Gene Amplification and Copy Gain in NSCLC

The primary aim of this research was to comprehensively assess ALK amplification and ALK gene copy number increases in a large population of non-small-cell lung cancer patients in order to determine the effects on mRNA and protein expression. Methods : The ALK locus number status was determined in 578 NSCLC cases by fluorescence in situ hybridization, according to the author. In addition, ALK immunohistochemistry and ALK mRNA in situ hybridization were performed. In situ hybridization, none of those carrying ALK immunohistochemical expression or ALK mRNA expression demonstrated by in situ hybridization.

Source link: https://doi.org/10.3390/ijms21144927


ALK Gene Rearrangements in Lung Adenocarcinomas: Concordance of Immunohistochemistry, Fluorescence In Situ Hybridization, RNA In Situ Hybridization, and RNA Next-Generation Sequencing Testing

Introduction: The 2018 updated molecular diagnostic testing recommendations for patients with advanced lung cancer included ALK immunohistochemistry results as an equivalent to fluorescence in situ hybridization procedures used in 2013. The aim of this review was to compare the results of ALK IHC, FISH, RNA next-generation sequencing, and RNA in situ hybridization with available clinical data. Two of the four discordant cases were ALK positive by FISH but not by IHC, RNA NGS, and RNA ISH. The remaining two cases failed RNA NGS testing, one of which was IHC negative, FISH positive, RNA ISH negative, and the other was IHC positive, FISH positive, RNA ISH negative, and RNA ISH negative, and the second was IHC positive, FISH positive, RNA ISH negative, RNA ISH negative, RNA ISH negative, RNA ISH negative, RNA ISH negative, RNA ISH negative, RNA ISH negative, FISH negative, FISH positive, FISH NGS negative, RNA ISH negative, RNA ISH negative, ISH negative, RNA ISH negative, RNA ISH negative, FISH negative, RNA ISH negative, RNA ISH negative, RNA ISH negative, RNA ISH negative, RNA ISH negative, RNA ISH negative, ISH negative, ISH negative, ISH negative, ISH negative, RNA ISH negative The RNA NGS detected one rare and one novel ALK fusion. The FISH result was positive, in cases of discordance with available RNA NGS, but the IHC and ISH findings were negative.

Source link: https://doi.org/10.1016/j.jtocrr.2021.100223


Targeting anaplastic lymphoma kinase (ALK) gene alterations in neuroblastoma by using alkylating pyrrole-imidazole polyamides.

Although emerging resistance to ALK tyrosine kinase inhibitors is expected, novel anti-ALK drug discovery is required in order to overcome potential drug resistance against ATP-competitive kinase inhibitors. Total and phosphorylated ALK's expression was reduced by CCC-003 therapy, but not by treatment with a mismatch polyamide despite no common pattern within the ALK gene region. In a human neuroblastoma xenograft mouse model, CCC-003 is preferentially linked to the F1174L mutation, which has significantly reduced tumor formation. Our results show that the specific linking of CCC-003 to mutated DNA within the ALK gene promotes its anti-tumor activity in a manner that is distinct from those of other ALK inhibitors. In summary, our latest review shows that pyrrole-imidazole polyamide (ALK) inhibitor CCC-003 has been shown to be safe for the treatment of neuroblastoma, providing a potential solution to the problem of tyrosine kinase inhibitor resistance.

Source link: https://doi.org/10.1371/journal.pone.0257718


Anaplastic lymphoma kinase (ALK) gene alteration in signet ring cell carcinoma of the gastrointestinal tract

We investigated the presence of anaplastic lymphoma kinase gene rearrangements in signet ring cancers arising in the stomach and colon. Methods: Histologically established cases of ringing adenocarcinoma of the stomach or colon were discovered. The presence of the classic ALK and EML4 fusion gene was first determined by fluorescence in-situ hybridization methods. Results: We had 42 cases of signet ring carcinoma diagnosed between 2001 and 2011, including 25 gastric and 17 colon cancer. According to FISH, one of 42 patients was positive for ALK translocation by FISH using the normal criteria of at least 15% positive cells for the break-apart signal. Two out of 42 patients tested positive for IHC with two previously validated monoclonal antibodies revealed zero of 42 cases positive. Conclusions: ALK gene rearrangement is extremely unusual in intestinal cancers, and a signet ring cell histology based on signet ring cell histology did not significantly raise the detection rate.

Source link: https://doi.org/10.1177/1758834014567117


Detection of ALK Gene Rearrangement in Cell-free RNA from Lung Cancer Malignant Pleural Effusion

The aim of this study was to determine the possibility of monitoring ALK gene rearrangement in cell-free RNA of the supernatant from malignant pleural effusion's malignant pleural effusion's supernatant. In the supernatant, the amount of cf-RNA was higher than in matching sera, according to the study. In ALK gene rearrangement cases, 100% of the supernatant and cell blocks were 100% between the supernatant and cell blocks, while 0% between sera and cell blocks was 0%.

Source link: https://doi.org/10.1155/2020/6124106

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions